

Daurat G. MD, Besse-Moreau M. MD and the Regional Coordinators of Hemovigilance (CRH).

Supported by the SFVTT (Societe Francaise de Vigilance et Therapeutique Transfusionnelle)

IHN symposium Brussels 20-22 Feb 2013

# Background

- Increasing demand for PC
  - □ +10 % from 2009 to 2011
- Decreasing supply of Apheresis PC
  - Deferral of non nulliparous women from apheresis...

Response :

Higher production of Pooled PC

Meanwhile : 2009-2011 first data on donors' hemovigilance

# Objectives

To compare the global risk level of Apheresis PC versus Pooled PC both for

#### donors

and

recipients

#### Method

- 23 French regions (96% of French pop.)
- Merge of detailled data sets on :
  - Donations
  - Serious Adverse Reactions (SAR) of donors
  - Transfusions
  - All Adverse Reactions (AR) of recipients
- 2009 2011

Provided by the Regional Coordinators of Hemov. SAR, validated by expert groups Results

## Recipients : PC transfused

Transfusion : number of transfused PC

	APC		PPC		Total PC	
2009	176,497	71%	73,377	29%	249,874	
2010	160,288	<mark>61%</mark>	103,366	39%	263,654	
2011	140,962	51%	136,364	49%	277,326	
Total	477,747	<mark>60%</mark>	313,107	40%	790,854	

## **Recipients : adverse reactions**

#### Adverse reactions of recipients:

Rates for 1,000 transfused PC

	Grade 1	Grade 2	Grade 3	Grade 4	<b>All*</b> \	SA	<b>XR</b> **
APC	6.34	0.25	0.19	0.02	6.87		0.46
PPC	3.17	0.15	0.12	0.01	3.50		0.28
				*	$n - 10^{-6}$	**	$n - 10^{-5}$

## Recipients

#### Kind of Serious Adverse Reactions



#### **Donors : donations**

#### Donations

Donations by sex	20	10	2011		
	APC	W. Blood	APC	W. Blood	
Males	83,753	1,207,250	80,914	1,279,831	
Females	58,015	1,079,136	43,413	1,156,468	
Total	141,768	2,286,386	124,327	2,436,299	

## **Donors : SAR**

#### **Donors' Serious Adverse Reactions**

#### Rates for 1,000 Donations

	Donors' SAR by sex	20	10	2011		
		APC	W. Blood	APC	W. Blood	
$\langle$	M	0.76	0.24	1.82	0.98	
$\langle$	F	1.38	0.50	3.64	1.54	
	Both	<u></u>	0.35	2.45	1.22	

# Summary : Combined Donors' and Recipients' hazard

• Individual level (rates per 1,000)

	APC	PPC (W. Blood)
Donors' SAR 2010-2011	1.69	0.8
Recipients' AR 2009-2011	6.87	3.50
Recipients' SAR 2009-2011	0.46	0.28

 Population level: switch from APC to PPC
 Hazard for APC Donors' : suppressed without increase of risk for whole blood Donors'

Two fold reduction of global risk for PC Recipients

## Feasability and costs

- No known difference of efficacy PPC/APC
  Some situations require APC
- Yearly, 2.5 millions of WB donations could provide 400,000 PPC

Demand < 300,000

Costs :

(France for a 4.5 10<sup>11</sup> bag incl. dispensation)

APC : 489.51 €

PPC : 337.59 € (-31%)

#### Conclusion

- Compared to PPC, APC are
  - at higher risk both for Donors and Recipients
  - at higher cost
  - have the same efficacy
- Hemovigilance usefullness
  - <u>Recipients</u> : already allowed partial switch to PPC
  - <u>Donors</u> : improved apheresis practice, could lead to further changes in PC supply policy